Author: admin

  • WCH Tokyo 25 preview: women’s 1500m | News | Tokyo 25

    WCH Tokyo 25 preview: women’s 1500m | News | Tokyo 25

    • Faith Kipyegon has the chance to equal Hicham El Guerrouj’s record gold-medal haul
    • Her compatriot Nelly Chepchirchir will be buoyed by Diamond League Final win
    • Diribe Welteji, Jessica Hull and Nikki Hiltz are among the medal contenders 

    Despite having contested only three official races this year, Faith Kipyegon starts as the big gold-medal favourite at the World Athletics Championships Tokyo 25, especially after one of those races featured a world record.

    The Kenyan star opened her campaign in late April at the Diamond League meeting in Xiamen, just missing the world 1000m record with 2:29.21 – the third-fastest time in history behind her own PB and the world record.

    Two months later, she produced the fastest mile performance in history (4:06.42) in an unofficial exhibition event. Shortly after that she competed at the Diamond League meeting in Eugene and improved her own world 1500m record, which now stands at 3:48.68. 

    She also attempted the world 3000m record at the Diamond League meeting in Silesia in August, but missed it by less than a second. Nevertheless, she was satisfied with the result as she became the only woman to come within five seconds of the long-standing world record of 8:06.11 set by Wang Junxia in 1993.

    “It is all about Tokyo now,” she said after the race.

    The 31-year-old has won three Olympic and three world 1500m titles – more than any other woman in the history of the event – and remains unbeaten over the distance for four years. If she continues this streak at the World Championships, she will equal the gold medal haul achieved by Hicham El Guerrouj – the only runner with four world 1500m titles.

    Her closest pursuer Gudaf Tsegay, who ran 3:50.62 this year, is entered in the 5000m and 10,000m at WCH Tokyo 25. Since the longest track event and the 1500m heats both fall on the first competition day, Saturday 13 September, the Ethiopian has decided to skip the shorter distance. The 1500m semifinals are on 14 September, and the final is two days after that.

    Kipyegon’s compatriot Beatrice Chebet – fifth on this season’s 1500m top list – made the same decision as Tsegay. However, if everything goes to plan, the trio will reunite in the final of the 5000m – an event in which Kipyegon is also the defending champion. 

    In Tsegay’s absence, Ethiopia’s leading contender for a 1500m medal is Diribe Welteji, the world silver medallist two years ago. When Kipyegon set her world record in Eugene, the 22-year-old finished second in a personal best of 3:51.44, which places her eighth on the all-time list.

    Three spots ahead of her on that world all-time list stands Australia’s Olympic silver medallist Jessica Hull, who narrowly lost this year’s Diamond League Final in Zurich when Kenya’s Nelly Chepchirchir beat her in a photo finish. Chepchirchir, who also won at the Diamond League meetings in Doha, Rabat, Paris and Monaco, is also among the contenders in Tokyo.

    The US team will be led by national champion Nikki Hiltz, who won at the penultimate Diamond League meeting in Brussels in a season’s best of 3:55.94. 

    Laura Muir has placed in the top six at the last five World Championships. She will be part of the British team again, while her compatriot Georgia Hunter Bell – who is the sixth-fastest woman in the 1500m this year and the Olympic bronze medallist – has decided to focus on the 800m. 

    Lucijan Zalokar for World Athletics

     

    Continue Reading

  • As Windows 10 reaches end of life, Windows 11 is LOSING market share

    As Windows 10 reaches end of life, Windows 11 is LOSING market share

    Next month sees Windows 10 finally reaching the end of (mainstream) support. Microsoft has been pushing people towards Windows 11 for what feels like forever, and it worked – for a while.

    The latest market figures show that this is changing. The statistics for August 2025 from statcounter Global Stats show a marked drop in Windows 11’s share of the desktop market.

    Rewinding a little bit through time, June 2025 was a significant month because it marked the point at which Windows 11 finally caught up (well, very nearly) with Windows 10. Windows 11 managed to reach a market share of 47.98 percent of Windows desktops, compared to 48.76 percent for Windows 10.

    July 2025 saw Windows 11’s steady increase in popularity continuing, with a big jump for the latest version of Windows up to a 53.51 percent share of the market. Windows 10 trailed behind at 42.88 percent.

    But now the tide is turning. While Windows 11 remains more popular than Windows 10, there has been a very sudden drop in market share. As of August 2025, Windows 11 has a 49.08 percent share of the desktop Windows version market. This compares to 45.53 percent for Windows 10.

    The downturn will be disappointing for Microsoft, and it is somewhat surprising for everyone else. It is all the more shocking when you consider we are now just weeks away from Windows 10 reaching the end of life.

    It is difficult to pull apart the numbers to determine just why Windows 11 is suffering in this way, but there is a further surprise. Not only is Windows 10 increasing in popularity, but so is Windows 7. Yes, Windows 7.

    It would be an exaggeration to say that the ancient Windows 7 is enjoying a resurgence, but a jump in market share to 3.59 percent at this stage of the game is remarkable.

    So close to the death of Windows 10, it would be reasonable to see its share of the market continually, but slowly reducing. To see it increasing is just weird.

    It does seem to indicate an astonishing resistance to Windows 11 with so many millions of systems still being powered by an incredibly old operating system which is not far from being dropped by the company responsible for it. Windows 10 remains a beloved version of Windows, and people wanting to hang on to it is understandable – especially anyone wanting to avoid the onslaught of AI. But Windows 7 is another matter.

    It will be interesting to see what happens with the market share statistics for the rest of 2025 and the early part of 2026. Will Microsoft’s persistence force people towards Windows 11, or will Windows 10 continue to maintain a significant presence?

    Image credit: NikolayShubin / depositphotos


    Continue Reading

  • Vandromme captures US Open girls’ title; now on 23-match winning streak

    Vandromme captures US Open girls’ title; now on 23-match winning streak

    No. 14 seed Jeline Vandromme continued her superb summer form by capturing the US Open girls’ singles title with a 7-6(2), 6-2 defeat of qualifier Lea Nilsson in the final, coming back from 4-2 down in the first set.

    Watched by compatriot and former World No. 1 Kim Clijsters, 17-year-old Vandromme became the first Belgian girl to lift a major trophy since An-Sophie Mestach at the 2011 Australian Open, and first to do so at the US Open since Kirsten Flipkens in 2003. She is the fifth Belgian girls’ singles Grand Slam champion in the Open Era following Mestach, Flipkens, Justine Henin (Roland Garros 1997) and Nancy Feber (Wimbledon 1993).

    A classically-trained pianist who was a student at the Conservatory of Bruges, Vandromme has said that only one thing links her two passions: “You have to be disciplined in both things, and you have to practice a lot, every day,” she told itftennis.com this week. “I don’t know for sure that piano helps tennis, but I love playing both.”

    The discipline has been on show in her nascent tennis career lately, as Vandromme is now on a 23-match winning streak at all levels. She spent July and August playing the ITF World Tour, collecting three consecutive titles — the Roehampton ITF W35 as a qualifier, then back-to-back ITF W15s in Monastir — and cutting her PIF WTA Ranking from No. 754 to No. 495 in four weeks.

    She’s also now won 33 sets in a row. Vandromme last dropped a set in the Roehampton final, in which she defeated Shi Han 7-6(4), 5-7, 7-5. Following that, she won both Monastir events and the US Open title without the loss of a set. Her run in Flushing Meadows included a 6-3, 6-2 third-round defeat of Australian Open girls’ finalist Kristina Penickova and a 6-3, 6-2 semifinal win over Roland Garros girls’ finalist Hannah Klugman.

    Vandromme conceded only 22 games in five matches to reach the final, but faced her stiffest opposition with the title on the line. Nilsson was the first player to stretch her as far as a tiebreak since the Roehampton final — appropriately, given the 17-year-old Swede’s battling run this week.

    After losing a 6-3, 4-6, 6-4 heartbreaker to Nadia Lagaev in the third round of the Repentigny junior event in Canada the previous week, Nilsson caught a 7 a.m. flight to New York the following morning — and had to play her first qualifying match that afternoon, which she eked out 5-7, 6-1, [10-7] over Ireland O’Brien. 

    But she still had the energy to dish out two of the main draw’s biggest upsets, taking out No. 1 seed Julieta Pareja 6-4, 3-6, 6-3 in the third round and defending champion Mika Stojsavljevic 0-6, 6-1, 6-1 in the semifinals. Nilsson was the first Swedish girl in a junior Slam final since Sofia Arvidsson at the 2001 Australian Open, and was bidding to become the first qualifier ever to win the US Open junior title. She has a WTA ranking of No. 992.


    Jimmie48/WTA

    A nip-and-tuck first set saw Vandromme struggle to find the balance between power and safety as Nilsson delivered solid defense with a few excellent net forays mixed in. Vandromme fired five winners — nearly half her first-set total of 11 — in the first game alone but was nonetheless broken, and reined in her aggression to reel Nilsson in from 4-2 down.

    Once Vandromme had the tiebreak under her belt, though, she loosened up and showed what she was capable of in full flow. Boasting a major weapon in her forehand, Vandromme danced around it with beautiful footwork to unload repeatedly and raise her tally of winners to 25. 

    “I think I played a very good opponent, to start with,” Vandromme told press afterwards. “Lea played an incredible week and today also. I had a bit of nerves before the match, I would say, but I think I handled them good. I tried to play my level, my game, and it worked out really great.

    “I just tried to not focus on the fact that I’m 2-4 or 0-2 down. I just tried to focus on every point, every shot that I make, on my plan, and my tasks on court. Then I kind of forgot the score. I mean, I’m just trying to play every point and doing what I have to do. Then I don’t have extra pressure or I don’t feel the negative emotions coming up when I’m down.

    “Of course you start to feel the legs a bit when you go far into the tournament, like in the final now. But when the adrenaline takes over, then all I just felt was energy. Yeah, the will to win every point was so big that I don’t feel any fatigue or pain.”

    Vandromme didn’t have much time to celebrate her singles win: it was into the shower, a change of clothes and a quick bite to eat on the exercise bike before she was back out on court for the girls’ doubles final alongside Lithuania’s Laima Vladson as the No. 4 seeds.

    Alena Kovackova, Jana Kovackova - US Open 2025


    Elsa/Getty Images

    However, Vandromme was denied the double crown by Czech sisters Alena and Jana Kovackova, the No. 3 seeds, who raced to a 6-2, 6-2 victory. It’s a second major girls’ doubles title for 17-year-old Alena, who was the 2023 Wimbledon champion alongside Laura Samson, and a first for her younger sister Jana.

    The 15-year-old becomes the first 2010-born player to claim a junior Grand Slam title; she’s already the highest-ranked 2010-born player at No. 642, having compiled a 24-7 pro record including two ITF titles this year. Alena, meanwhile, is ranked at No. 640, and qualified for her first WTA main draw in July in Prague.

    The Kovackovas are the second sister act to lift a Grand Slam girls’ doubles trophy this year after American twins Annika and Kristina Penickova were victorious at the Australian Open — defeating the Kovackovas in the final — and the first to do so in US Open history.

    Continue Reading

  • New Stellantis CEO calls for EU to help support car sector

    New Stellantis CEO calls for EU to help support car sector

    (Reuters) -The new chief executive of carmaker Stellantis has urged the European Union to show flexibility on the transition to electric vehicles in order to protect the auto industry.

    “A strategic dialogue is very important, but now it’s vital to act with urgency. There is no time for delays,” said Antonio Filosa, who became Stellantis CEO in June.

    European Commission President Ursula von der Leyen is set to host automotive sector executives on September 12 to discuss the future of the sector, which is facing twin threats of Chinese competition in electric vehicles and U.S. tariffs.

    Filosa, head of a group whose brands include Fiat, Alfa Romeo, Peugeot, Chrysler, Jeep, and Opel, called on the European Commission to support the sale of cars such as hybrids to bring down the average age of vehicles on the road.

    “A European policy that encourages the replacement of older cars with new cars and a wider choice of powertrains would have a greater impact on global CO2 emissions than the annual new car market does,” he said in a joint interview with Italy’s Il Sole 24 Ore and France’s Les Echos.

    Filosa said the Light Commercial Vehicle sector was facing an emergency and added that the period over which CO2 emissions in the category were calculated should be extended to five years from three.

    He also sought to dismiss speculation that Stellantis could seek a buyer for Maserati as he reviews its brand portfolio.

    “I want to make it clear that Maserati is not for sale, but we need to understand which products to develop and which long-term strategy to adopt for one of our most iconic brands,” he said.

    (Writing by Keith WeirEditing by Tomasz Janowski)

    Continue Reading

  • Nuvalent Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025

    Nuvalent Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025

    Rolling NDA submission for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC initiated under FDA’s RTOR program, with completion on track for the third quarter of 2025

    CAMBRIDGE, Mass., Sept. 7, 2025 /PRNewswire/ — Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today presented pivotal data for zidesamtinib, a novel investigational ROS1-selective inhibitor, in TKI (tyrosine kinase inhibitor) pre-treated patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) from its global ARROS-1 Phase 1/2 clinical trial as part of the Presidential Symposium at the IASLC 2025 World Conference on Lung Cancer (WCLC 2025), being held in Barcelona, Spain. The presentation slides will be available on the Nuvalent website at www.nuvalent.com following the Presidential Symposium.

    The pivotal data presented today, initially announced in June 2025, serve as the foundation for the company’s ongoing rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zidesamtinib in TKI pre-treated patients with advanced ROS1-positive NSCLC. The FDA agreed to accept the NDA for participation in the Real-Time Oncology Review (RTOR) program, which facilitates earlier submission of topline efficacy and safety results prior to the submission of the complete application, to support an earlier start to the FDA’s evaluation of the application. The company is on track to complete its rolling NDA submission in the third quarter of 2025, and continues to engage with the FDA on potential opportunities for line-agnostic expansion.

    “There remains a clear need for new treatment options for patients with ROS1-positive NSCLC, particularly those who are unable to tolerate the currently available TKIs, and those whose disease progresses with brain metastases or resistance mutations,” said Christopher Turner, M.D., Chief Medical Officer at Nuvalent. “We are encouraged by the data presented today, which we believe highlight the potential of zidesamtinib to deliver meaningful outcomes with a generally safe and well-tolerated safety profile. These data represent important progress toward our goal of offering a new standard of care for this patient community. Congratulations to the entire Nuvalent team and our collaborators for the achievement of this important milestone.”

    About Zidesamtinib and the ARROS-1 Phase 1/2 Clinical Trial

    Zidesamtinib is a novel brain-penetrant ROS1-selective inhibitor created with the aim to overcome limitations observed with currently available ROS1 inhibitors. Zidesamtinib is designed to remain active in tumors that have developed resistance to currently available ROS1 inhibitors, including tumors with treatment-emergent ROS1 mutations such as G2032R. In addition, zidesamtinib is designed for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and to avoid inhibition of the structurally related tropomyosin receptor kinase (TRK) family. Together, these characteristics have the potential to avoid TRK-related CNS adverse events seen with dual TRK/ROS1 inhibitors and to drive deep, durable responses for patients across all lines of therapy. Zidesamtinib has received breakthrough therapy designation for the treatment of patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC) who have been previously treated with 2 or more ROS1 tyrosine kinase inhibitors and orphan drug designation for ROS1-positive NSCLC.

    Zidesamtinib is currently being investigated in the ARROS-1 trial (NCT05118789), a first-in-human Phase 1/2 clinical trial for patients with advanced ROS1-positive NSCLC and other solid tumors. The completed Phase 1 portion enrolled ROS1-positive NSCLC patients who previously received at least one ROS1 TKI, or patients with other ROS1-positive solid tumors who had been previously treated. The Phase 1 portion of the trial was designed to evaluate the overall safety and tolerability of zidesamtinib, with additional objectives including determination of the recommended Phase 2 dose (RP2D), characterization of the pharmacokinetic profile, and evaluation of preliminary anti-tumor activity. The ongoing global, single arm, open label Phase 2 portion is designed with registrational intent for TKI-naïve and TKI pre-treated patients with advanced ROS1-positive NSCLC.

    About Nuvalent

    Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Nuvalent’s strategy, business plans, and focus; the expected timing of data announcements and NDA submissions; the clinical development program for zidesamtinib; the potential benefits and effects of Nuvalent’s product development candidates; the design of Nuvalent’s clinical trials, including for the ARROS-1 trial its intended pivotal registration-directed design; the potential of Nuvalent’s pipeline programs, including zidesamtinib; Nuvalent’s research and development programs for the treatment of cancer; and risks and uncertainties associated with drug development. The words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “aim,” “goal,” “intend,” “believe,” “expect,” “estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target” or the negative of these terms and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. You should not place undue reliance on these statements or the scientific data presented.

    Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties, and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation: risks that Nuvalent may not fully enroll its clinical trials or that enrollment will take longer than expected; unexpected concerns that may arise from additional data, analysis, or results obtained during preclinical studies or clinical trials; the risk that results of earlier clinical trials may not be predictive of the results of later-stage clinical trials; the risk that data from our clinical trials may not be sufficient to support registration and that Nuvalent may be required to conduct one or more additional studies or trials prior to seeking registration of our product candidates; the occurrence of adverse safety events; risks that the FDA may not approve our potential products on the timelines we expect, or at all; risks of unexpected costs, delays, or other unexpected hurdles; risks that Nuvalent may not be able to nominate drug candidates from its discovery programs; the direct or indirect impact of public health emergencies or global geopolitical circumstances on the timing and anticipated timing and results of Nuvalent’s clinical trials, strategy, and future operations; the timing and outcome of Nuvalent’s planned interactions with regulatory authorities; and risks related to obtaining, maintaining, and protecting Nuvalent’s intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Nuvalent’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, as well as any prior and subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Nuvalent’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Nuvalent explicitly disclaims any obligation to update any forward-looking statements.

    SOURCE Nuvalent, Inc.

    Continue Reading

  • Microsoft cloud platform hit by cable cuts in Red Sea – Tech

    Microsoft cloud platform hit by cable cuts in Red Sea – Tech

    Global tech giant Microsoft on Sunday said network traffic for its Azure cloud computing platform was experiencing increased delays in parts of the Middle East due to “undersea fibre cuts” in the Red Sea.

    Microsoft did not provide an explanation for what caused the cuts to the submarine lines, but noted its network had been affected since Saturday.

    “Network traffic that does not traverse through the Middle East is not impacted,” the company said in a statement.

    The internet access monitoring organisation NetBlocks noted that a series of submarine cable outages in the Red Sea has degraded internet connectivity in several countries, including in India and Pakistan.

    Global internet and telecom cables have followed shipping routes through the Red Sea, but there has been growing anxiety about the state of the lines after Yemen’s Houthi rebels began attacking passing merchant vessels in late 2023, in actions the group said were in solidarity with the Palestinians amid the Israeli war on Gaza.

    The laying and operation of underwater cables have long been the preserve of a consortium of large telecoms operators, but internet giants have largely taken over in recent years as they strive to keep up with ballooning flows of data.

    About 1.4 million kilometres (nearly 900,000 miles) of fibre optic cables are laid on the ocean floor, enabling the provision of essential services such as trade, financial transactions, public services, digital health and education around the world.

    Damage to submarine cables is not uncommon.

    According to the International Cable Protection Committee, there are an average of 150 to 200 outages per year worldwide, or around three incidents a week.

    Fishing and anchoring are believed to be responsible for the vast majority of recorded damage to the lines.

    Natural hazards to the cables also include ageing, abrasions and equipment failure.

    Continue Reading

  • Japan PM Ishiba set to resign, source says – Reuters

    1. Japan PM Ishiba set to resign, source says  Reuters
    2. Japan’s PM Shigeru Ishiba resigns weeks after election debacle  Al Jazeera
    3. Japan PM decides to quit as opponents seek leadership election: reports  Dawn
    4. Shigeru Ishiba: the ’smile again’ Japanese PM who voters frowned on By Reuters  Investing.com
    5. Japan PM Ishiba says he will resign  France 24

    Continue Reading

  • ZIM vs SL Live Streaming Info, 3rd T20I: Zimbabwe, Sri Lanka face off in series decider; match details, full squads

    ZIM vs SL Live Streaming Info, 3rd T20I: Zimbabwe, Sri Lanka face off in series decider; match details, full squads

    With the three-match series locked at 1-1, Zimbabwe and Sri Lanka will lock horns in the third and final T20I at the Harare Sports Club on Sunday.

    Zimbabwe had stunned the visitor in the second T20I on Saturday to set up the series decider. The Sikandar Raza-led side bundled out Sri Lanka for 80, its second-lowest T20I total, and chased the target down inside 15 overs with five wickets in hand. It was Zimbabwe’s only second win against the Sri Lankans in eight T20I matches.

    Sri Lanka had clinched the series opener by four wickets after winning the ODI series 2-0.

    ZIM vs SL 3rd T20I – Match Details

    When will the third T20I between Zimbabwe and Sri Lanka take place?

    The third T20I between Zimbabwe and Sri Lanka will be played on Sunday, September 7.

    Where will the third T20I between Zimbabwe and Sri Lanka be held?

    The third T20I between Zimbabwe and Sri Lanka will take place at the Harare Sports Club.

    At what time will the third T20I between Zimbabwe and Sri Lanka start?

    The third T20I between Zimbabwe and Sri Lanka will begin at 5 PM IST. The toss is schedule for 4:30 PM IST.

    Where to watch the live telecast of the third T20I between Zimbabwe and Sri Lanka in India?

    The third T20I between Zimbabwe and Sri Lanka will not be televised live on any TV channel in India.

    Where to watch the live stream of the third T20I between Zimbabwe and Sri Lanka in India?

    The third T20I between Zimbabwe and Sri Lanka will be streamed live on the FanCode app and website in India.

    THE SQUADS

    Zimbabwe: Sikandar Raza (c), Brian Bennett, Ryan Burl, Brad Evans, Trevor Gwandu, Clive Madande, Tinotenda Maposa, Tadiwanashe Marumani, Wellington Masakadza, Tony Munyonga, Tashinga Musekiwa, Blessing Muzarabani, Dion Myers, Richard Ngarava, Brendan Taylor, Sean Williams.

    Sri Lanka: Charith Asalanka (c), Pathum Nissanka, Kusal Mendis, Kusal Perera, Nuwanidu Fernando, Kamindu Mendis, Kamil Mishara, Vishen Halambage, Dasun Shanaka, Dunith Wellalage, Chamika Karunaratne, Maheesh Theekshana, Dushan Hemantha, Dushmantha Chameera, Binura Fernando, Nuwan Thushara, Matheesha Pathirana.

    Published on Sep 07, 2025

    Continue Reading

  • FEI Dressage Pony for Sale: Falco

    FEI Dressage Pony for Sale: Falco

    Name: Falco
    Breed: Dutch Welsh pony
    Year of Birth: 2013
    Sire: Leuns Veld’s Winston
    Dam sire: Hagelkruis Valentijn
    Gender: Gelding
    Height: 148 cm (149,9 cm with shoes)
    Price category: 150,000 – 200,000 euro

    Falco is the 2024 Swedish Pony Champion and a triple European Championship Team Pony, having twice won team bronze.

    This eye-catching palomino is one of Europe’s top contending international dressage ponies with an impressive performance record. He competed at the European Pony Championships in 2021, 2024 and 2025 with two different riders for The Netherlands and Sweden, winning team bronze in 2021 and 2024 and placing 15th in the Kur to Music finals in 2025.

    He won the 2024 Swedish Pony Championships and captured bronze in 2025.  Falco is a very experienced pony with international wins and results up to 74%. He has competed in many international shows since 2020, including Hagen Future Champions and the Sweden International Horse Show.

    At Future Champions CDIO-P in Hagen

    In the same ownership for the past five years, Falco is a member of the family. Sadly his rider has aged out of ponies, while Falco is still in his prime and, therefore, looking for a new home.  

    Falco is the pony that made all dreams come true, always trying his heart out and never having a bad day. He is very well trained and is a fantastic dance partner. He is an energetic pony with natural go. 

    He is very easy to travel with and has always been very fit and healthy.

    A loving home is absolutely necessary to consider a sale. 

    Located in Stockholm, Sweden

    Video on request or ClipMyHorse

    Winning two tests at the 2025 CDI Sint-Truiden

    Owner Contact info:

    Continue Reading

  • Google Gemini labeled ‘High Risk’ for kids and teens in new safety review

    Google Gemini labeled ‘High Risk’ for kids and teens in new safety review

    Google’s flagship AI platform, Gemini, has been rated “high risk” for children and teens in a new safety assessment released by nonprofit watchdog Common Sense Media. The report raises serious concerns about the platform’s ability to protect young users from inappropriate content and psychological harm.

    Filters aren’t enough, experts say

    While Gemini includes safety filters for users under 13 and teens, Common Sense Media found that these versions are essentially adult models with superficial safeguards layered on top. The organization warned that Gemini can still surface “inappropriate and unsafe” material — including content related to sex, drugs, alcohol, and mental health advice that may be harmful to emotionally vulnerable youth.“Gemini gets some basics right, but it stumbles on the details,” said Robbie Torney, Senior Director of AI Programs at Common Sense Media. “An AI platform for kids should meet them where they are, not take a one-size-fits-all approach to kids at different stages of development”.

    AI and mental health risks

    The report comes amid growing scrutiny of AI’s role in teen mental health. Recent lawsuits against OpenAI and Character.AI allege that chatbot interactions contributed to teen suicides. Gemini’s potential to deliver unsafe advice — even unintentionally — has amplified calls for stricter oversight and child-specific design standards.

    Apple’s involvement raises stakes

    The timing of the report is especially critical as leaks suggest Apple may integrate Gemini into its upcoming AI-powered Siri. If true, this could expose millions of young users to the platform unless Apple addresses the flagged safety issues

    Google responds

    Google pushed back against the assessment, stating that it has policies and safeguards in place for users under 18, and regularly consults external experts to improve protections. The company acknowledged that some responses weren’t working as intended and said it has added new safeguards to address those gaps


    Continue Reading